AR042369A1 - Uso de un inhibidor especifico de fosfodiesterasa 4 en la fabricacion de un medicamento para la profilaxis o para tratar la enfermedad pulmonar obstructiva cronica - Google Patents
Uso de un inhibidor especifico de fosfodiesterasa 4 en la fabricacion de un medicamento para la profilaxis o para tratar la enfermedad pulmonar obstructiva cronicaInfo
- Publication number
- AR042369A1 AR042369A1 ARP000100863A ARP000100863A AR042369A1 AR 042369 A1 AR042369 A1 AR 042369A1 AR P000100863 A ARP000100863 A AR P000100863A AR P000100863 A ARP000100863 A AR P000100863A AR 042369 A1 AR042369 A1 AR 042369A1
- Authority
- AR
- Argentina
- Prior art keywords
- inhibitor
- manufacture
- pulmonary disease
- chronic obstructive
- obstructive pulmonary
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/30—Copper compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
El uso de un inhibidor específico de PDE4 (fosfodiesterasa 4) en la fabricación de un medicamento para la profilaxis o para tratar COPD (enfermedad pulmonar obstructiva crónica), en el que el inhibidor tiene una relación de IC50 de aproximadamente 0,1 o más en relación con la IC50 para la forma de PDE4 que une R-rolipram con una alta afinidad dividida por al IC50 para la forma catalítica que une R-rolipram con una baja afinidad, excluyendo cis-[4-ciano-4-(3-ciclopentiloxi-4-metoxifenil)ciclohexan-1-carboxilato].
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12231599P | 1999-03-01 | 1999-03-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR042369A1 true AR042369A1 (es) | 2005-06-22 |
Family
ID=22401990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP000100863A AR042369A1 (es) | 1999-03-01 | 2000-02-28 | Uso de un inhibidor especifico de fosfodiesterasa 4 en la fabricacion de un medicamento para la profilaxis o para tratar la enfermedad pulmonar obstructiva cronica |
Country Status (30)
Country | Link |
---|---|
US (1) | US6670394B1 (es) |
EP (1) | EP1156799A4 (es) |
JP (1) | JP2002538114A (es) |
KR (1) | KR20010102459A (es) |
CN (1) | CN1349403A (es) |
AP (1) | AP2001002248A0 (es) |
AR (1) | AR042369A1 (es) |
AU (1) | AU772583B2 (es) |
BG (1) | BG105953A (es) |
BR (1) | BR0008603A (es) |
CA (1) | CA2366036A1 (es) |
CO (1) | CO5160248A1 (es) |
CZ (1) | CZ20013149A3 (es) |
DZ (1) | DZ3019A1 (es) |
EA (1) | EA200100930A1 (es) |
HK (1) | HK1043935A1 (es) |
HU (1) | HUP0200288A3 (es) |
ID (1) | ID29888A (es) |
IL (1) | IL144992A0 (es) |
MA (1) | MA25522A1 (es) |
NO (1) | NO20014222L (es) |
NZ (1) | NZ513695A (es) |
OA (1) | OA11842A (es) |
PE (1) | PE20001505A1 (es) |
PL (1) | PL352816A1 (es) |
SK (1) | SK12372001A3 (es) |
TR (1) | TR200102514T2 (es) |
UY (1) | UY26040A1 (es) |
WO (1) | WO2000051598A1 (es) |
ZA (1) | ZA200107186B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2362101A (en) * | 2000-05-12 | 2001-11-14 | Astrazeneca Ab | Treatment of chronic obstructive pulmonary disease |
US20040005995A1 (en) * | 2001-07-26 | 2004-01-08 | Edelson Jeffrey D | Method for reducing exacerbations associated with copd |
AR029984A1 (es) * | 2000-07-27 | 2003-07-23 | Smithkline Beecham Corp | Metodo para reducir las exacerbaciones asociadas copd ambito |
WO2002088079A2 (en) * | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
AR039385A1 (es) | 2002-04-19 | 2005-02-16 | Astrazeneca Ab | Derivados de tioxantina como inhibidores de la mieloperoxidasa |
ES2335498T3 (es) | 2003-03-10 | 2010-03-29 | Nycomed Gmbh | Nuevo proceso para la preparacion de reflumilast. |
WO2004087148A1 (ja) * | 2003-03-31 | 2004-10-14 | Kyowa Hakko Kogyo Co. Ltd. | 肺疾患の治療および/または予防剤 |
WO2005056009A1 (ja) * | 2003-12-12 | 2005-06-23 | Kyowa Hakko Kogyo Co., Ltd. | 肺疾患治療剤 |
MY140748A (en) | 2004-12-06 | 2010-01-15 | Astrazeneca Ab | Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy |
AU2006224619B2 (en) | 2005-03-16 | 2012-06-07 | Takeda Gmbh | Taste masked dosage form containing roflumilast |
TW200804383A (en) | 2006-06-05 | 2008-01-16 | Astrazeneca Ab | New compounds |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3251587B2 (ja) * | 1992-04-02 | 2002-01-28 | スミスクライン・ビーチャム・コーポレイション | 炎症疾患の治療および腫瘍壊死因子の産生阻害に有用な化合物 |
HU225869B1 (en) * | 1992-04-02 | 2007-11-28 | Smithkline Beecham Corp | Compounds with antiallergic and antiinflammatory activity and pharmaceutical compns. contg. them |
ES2229221T3 (es) | 1993-06-18 | 2005-04-16 | Smithkline Beecham Corporation | Procedimiento de identificacion de un inhibidor de pde iv. |
US5728705A (en) * | 1993-10-04 | 1998-03-17 | The Trustees Of Columbia University In The City Of New York | Method of inducing vasorelaxation to treat pulmonary hypertension |
CZ283564B6 (cs) * | 1993-11-26 | 1998-05-13 | Pfizer Inc. | 3-Aryl-2-isoxazolin-5-hydroxamové kyseliny a farmaceutické prostředky na jejich bázi |
UY25338A1 (es) | 1998-01-07 | 2001-08-27 | Smithkline Beecham Corp | Método para tratar copd |
-
2000
- 2000-02-27 DZ DZ000038A patent/DZ3019A1/xx active
- 2000-02-28 AR ARP000100863A patent/AR042369A1/es not_active Application Discontinuation
- 2000-02-28 UY UY26040A patent/UY26040A1/es unknown
- 2000-02-29 PE PE2000000165A patent/PE20001505A1/es not_active Application Discontinuation
- 2000-03-01 AU AU33869/00A patent/AU772583B2/en not_active Ceased
- 2000-03-01 PL PL00352816A patent/PL352816A1/xx not_active Application Discontinuation
- 2000-03-01 KR KR1020017011096A patent/KR20010102459A/ko not_active Application Discontinuation
- 2000-03-01 EP EP00912074A patent/EP1156799A4/en not_active Withdrawn
- 2000-03-01 BR BR0008603-7A patent/BR0008603A/pt not_active Application Discontinuation
- 2000-03-01 AP APAP/P/2001/002248A patent/AP2001002248A0/en unknown
- 2000-03-01 NZ NZ513695A patent/NZ513695A/en unknown
- 2000-03-01 CN CN00806912A patent/CN1349403A/zh active Pending
- 2000-03-01 HU HU0200288A patent/HUP0200288A3/hu unknown
- 2000-03-01 IL IL14499200A patent/IL144992A0/xx unknown
- 2000-03-01 EA EA200100930A patent/EA200100930A1/ru unknown
- 2000-03-01 OA OA1200100226A patent/OA11842A/en unknown
- 2000-03-01 CO CO00014625A patent/CO5160248A1/es unknown
- 2000-03-01 US US09/914,703 patent/US6670394B1/en not_active Expired - Fee Related
- 2000-03-01 WO PCT/US2000/005227 patent/WO2000051598A1/en not_active Application Discontinuation
- 2000-03-01 TR TR2001/02514T patent/TR200102514T2/xx unknown
- 2000-03-01 ID IDW00200101869A patent/ID29888A/id unknown
- 2000-03-01 CA CA002366036A patent/CA2366036A1/en not_active Abandoned
- 2000-03-01 JP JP2000602066A patent/JP2002538114A/ja not_active Withdrawn
- 2000-03-01 CZ CZ20013149A patent/CZ20013149A3/cs unknown
- 2000-03-01 SK SK1237-2001A patent/SK12372001A3/sk unknown
-
2001
- 2001-08-30 ZA ZA200107186A patent/ZA200107186B/en unknown
- 2001-08-31 NO NO20014222A patent/NO20014222L/no not_active Application Discontinuation
- 2001-09-03 MA MA26314A patent/MA25522A1/fr unknown
- 2001-09-26 BG BG105953A patent/BG105953A/xx unknown
-
2002
- 2002-05-16 HK HK02103723.6A patent/HK1043935A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
DZ3019A1 (fr) | 2005-05-20 |
PL352816A1 (en) | 2003-09-08 |
EA200100930A1 (ru) | 2002-02-28 |
UY26040A1 (es) | 2000-09-29 |
HUP0200288A2 (hu) | 2002-05-29 |
IL144992A0 (en) | 2002-06-30 |
EP1156799A1 (en) | 2001-11-28 |
ID29888A (id) | 2001-10-18 |
EP1156799A4 (en) | 2004-11-10 |
CA2366036A1 (en) | 2000-09-08 |
CO5160248A1 (es) | 2002-05-30 |
NZ513695A (en) | 2001-09-28 |
PE20001505A1 (es) | 2001-02-08 |
KR20010102459A (ko) | 2001-11-15 |
CN1349403A (zh) | 2002-05-15 |
BG105953A (en) | 2002-05-31 |
WO2000051598A1 (en) | 2000-09-08 |
JP2002538114A (ja) | 2002-11-12 |
CZ20013149A3 (cs) | 2002-04-17 |
HK1043935A1 (zh) | 2002-10-04 |
NO20014222L (no) | 2001-10-29 |
ZA200107186B (en) | 2002-08-30 |
HUP0200288A3 (en) | 2003-08-28 |
SK12372001A3 (sk) | 2001-12-03 |
BR0008603A (pt) | 2001-12-26 |
MA25522A1 (fr) | 2002-10-01 |
AP2001002248A0 (en) | 2001-09-30 |
NO20014222D0 (no) | 2001-08-31 |
AU772583B2 (en) | 2004-04-29 |
US6670394B1 (en) | 2003-12-30 |
TR200102514T2 (tr) | 2002-04-22 |
AU3386900A (en) | 2000-09-21 |
OA11842A (en) | 2005-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR042369A1 (es) | Uso de un inhibidor especifico de fosfodiesterasa 4 en la fabricacion de un medicamento para la profilaxis o para tratar la enfermedad pulmonar obstructiva cronica | |
ECSP067043A (es) | Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis | |
ATE486840T1 (de) | Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür | |
AR013269A1 (es) | Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral | |
UY28041A1 (es) | Metodos de dosis bajas para el tratamiento de trastornos en los cuales la actividad del tnfa es perjudicial. | |
UY28213A1 (es) | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. | |
AR034900A1 (es) | Uso de una cantidad eficaz de un inhibidor de pde4 y un agente anticolinergico, bien en forma combinada sola o por separado, composiciones farmaceuticas que los comprenden, metodo para prepararlas, y uso de una composicion que comprende una cantidad eficaz de un inhibidor de pde4, una cantidad efica | |
BR0210253A (pt) | Processo para telomerização de olefinas não-cìclicas | |
BRPI0518290A2 (pt) | processo para a fabricaÇço de um composto alquenil aromÁtico sob baixas condiÇÕes de processo de vapor-para-àleo | |
AR034231A1 (es) | Composicion farmaceutica que contiene mosaprida y pancreatina | |
MY137766A (en) | Exemestane as chemopreventing agent | |
AR039633A2 (es) | Uso de un compuesto tipo cabergolina para preparar un medicamento para el tratamiento de la fibromialgia y el sindrome de fatiga cronica | |
PA8529701A1 (es) | Compuestos retinoides | |
PA8542901A1 (es) | Uso de (z)-2-ciano-3-hidroxi-but-2-acido enoico-(4-trifluorometilfenil)-amida para tratar la esclerosis multiple | |
CL2015001086A1 (es) | Combinación farmacéutica para el tratamiento y/o quimiosensibilizacion de tumores refractarios a drogas anticancerigenas | |
TWI349545B (en) | Pharmaceutical composition | |
IS2849B (is) | Notkun á írbesartani til framleiðslunnar á lyfjum sem eru notuð til að fyrirbyggja eða meðhöndla lungnaháþrýsting | |
SE0000303D0 (sv) | Novel compounds | |
TR199901206T2 (xx) | Diyabetik damar rahats�zl�klar�n�n �nlenmesi i�in bir ila� �retiminde katekol-O-metil transferaz inhibit�rlerinin kullan�lmas�. | |
AR030522A1 (es) | Tratamiento de quemaduras | |
AR030660A1 (es) | Composicion farmaceutica para la prevencion o el tratamiento de una enfermedad asociada con un exceso de la produccion de il-12 | |
BRPI0413718A (pt) | ativadores de plasminogênio tendo uma capacidade reduzida de ligar lisina | |
MX2023002773A (es) | Nitazoxanida para su uso en el tratamiento de covid-19. | |
WO2004089395A3 (en) | Use of an inhibitor of cathepsin-s or -b to treat or prevent chronic obstructive pulmonary disease | |
CL2004000840A1 (es) | Uso de una proteasa de coronavirus relacionados con el sindrome respiratorio agudo severo (sras) conjuntamente con un inhibidor de proteasas 3c de rinovirus para tratar el sras. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |